(CNN) The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the United States and Mexico.
The trial results appear consistent with the efficacy and safety profile the vaccine previously showed in a Phase 3 trial conducted in the United Kingdom, Dr. Gregory Glenn, president of research and development for Novavax, told CNN.
"Different continent, different population, different viruses floating around, and yet, we still see really good efficacy," Glenn said.
The study launched in December and enrolled 29,960 adults across 113 sites in the United States and six sites in Mexico.
Some of the participants were given a placebo and some were administered two doses of the Novavax vaccine 21 days apart.
Gregory Glenn, Glenn, Read
American, United States, Mexico, United Kingdom